To conclude, intermediate and low metabolisers (due to CYP2C19 LOF alleles) who were prescribed clopidogrel in the primary care setting had substantially increased risks of incident hospital-diagnosed strokes and MIs, compared with normal metabolisers. The gene discussed is CYP2C19; the disease is Stroke.